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INTRODUCTION 
Despite the fact that testis cancer accounts for only 1% of all male malignancies, it is the most common 
solid malignancy affecting males between the ages of 15 to 35 years. The management of germ cell 
tumors (GCT) of the testis has proved to be a model of success among solid tumors. This is due to 
tremendous advances during the past 2 decades, which have changed the once dismal prognosis for 
patients with advanced disease.1 Testicular cancer has, in fact, become one of the most curable of all solid 
neoplasms. Thirty years ago testicular cancer accounted for 11.4% of all cancer deaths in the 25 to 34 
year age group, with an overall 5 year survival rate of 64%.2 The most recent five-year survival rate for 
GCT of the testis in the United States was recently reported as being in excess of 90%.3
Improved prospects for cure and long-term disease free survival rate, are related to a better 
understanding of the natural history of testicular tumors, improved staging methods and surgical 
techniques, as well as to the introduction of effective platinum based combination chemotherapy.4 
Modifications to the surgical management of testis cancer have significantly reduced morbidity associated 
with the classical full bilateral retroperitoneal lymph node dissection. Template and nerve sparing 
retroperitoneal node dissections are now routinely employed in low stage nonseminomatous germ cell 
tumors (NSGCT), providing the patient with the benefit of accurate pathological staging combined with 
reduced morbidity. In addition, nerve sparing techniques have also been used in dissections for residual 
disease following chemotherapy.5
Chemotherapy for advanced GCT has undergone a number of important breakthroughs during the 
past three decades. In the 1960's the first major chemotherapeutic advance in metastatic NSGCT was 
described; a combination of chlorambucil, methotrexate and dactinomycin produced a response rate of 
30%.6 By the 1970's combination therapies such as vinblastine and bleomycin had been shown to produce 
objective responses; 57% complete response rates and 45% long-term disease-free survival rates were 
reported.7
The discovery of cisplatin as a highly effective anti-neoplastic agent in 1965,8 and its later use in 
germ cell tumors of the testis (GCT), was another important breakthrough. In 1974 the combination of 
cisplatin, vinblastine and bleomycin was investigated by the Indiana group.9 Of the 47 patients in the 
initial phase II study, 100% achieved a response rate. Thirty five (74%) patients achieved complete 
remission, the remaining patients achieved a partial remission. 
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In 1983 the combination of bleomycin, etoposide, and cisplatin (BEP) was first described by a group 
of investigators at the Royal Marsden Hospital.10 This combination was later compared in randomized 
studies to cisplatin, vinblastine and bleomycin (PVB) and found to be both less toxic and more effective. 
The use of BEP therefore became a milestone in the treatment of GCT of the testis and has become a 
widely used treatment for advanced disease.11-13
Since the late 1980's investigators have distinguished between low (good) risk and high (poor) risk 
disease, based on the diverse prognosis of patients with advanced GCT.14-15 In those patients with good 
risk disease, the objective is to reduce treatment toxicity while maintaining high rates of complete 
response. In this regard three cycles of BEP were found to be as effective as four cycles of BEP, in 
patients with good risk disease.14 On the other hand, studies in poor risk patients have focused on 
improving both response rates and survival. Numerous phase II and phase III studies have not led to very 
significant improvements in outcome in poor risk patients, who are fortunately rarely encountered 
today.16-17
PRINCIPLES OF SURGICAL MANAGEMENT OF TESTIS CANCER 
The principles which underlie the modern surgical treatment of GCT are based on the fact that testis 
cancer spreads in a predictable and stepwise fashion, with the notable exception of choriocarcinoma. The 
spermatic cord contains four to eight lymphatic channels that ascend into the retroperitoneum and fan out 
medially into the retroperitoneal lymph node chain. The first echelon of lymph nodes draining the right 
testis is located within the interaortocaval nodes at the level of the second vertebral body. The first 
echelon of nodes draining the left testis is located in the para-aortic region in an area bounded by the renal 
vein superiorly, aorta medially, ureter laterally and the origin of the inferior mesenteric artery inferiorly. 
Following spread to either the left or right primary echelon of nodes, subsequent spread may occur in a 
retrograde fashion to the common, external and inguinal nodes, or cephalad via the cysterna chyli, 
thoracic duct and supraclavicular nodes. Despite the predictability of lymph node metastasis in testis 
cancer, there is a failure rate of 5% with distant metastasis following node negative retroperitoneal 
lymphadenectomy (RPL).18 This is probably due to the fact that testicular lymphatics may very 
occasionally bypass retroperitoneal lymph nodes altogether and communicate directly with the thoracic 
duct. In a review of 104 consecutive cases of stage II NSGCT, Donohue et al, made a number of 
important observations confirming the predictability of lymphatic spread in testicular cancer.19 He 
reported that suprahilar lymph node spread was rare in stage IIA disease, unlike stage IIB disease, where 
suprahilar spread was not uncommon. In low stage disease the absence of contralateral nodal involvement 
was noted. In addition, in this series gonadal vein involvement was noted in a significant number of cases 
in both low and high stage II disease. These observations have important implications for the surgical 
management of testis cancer. 
Lymphatics of the epididymis drain into the external iliac chain; therefore, in locally extensive 
disease, epididymal involvement may be associated with positive pelvic nodes. Testis cancer that involves 
the scrotum may result in inguinal node metastases; in addition, prior scrotal surgery or retrograde spread 
from extensive retroperitoneal involvement may also cause inguinal metastases. Scrotal violation in the 
setting of orchiectomy for testis cancer has generally been condemned as compromising patient prognosis 
and for this reason, inguinal orchiectomy with high ligation of the spermatic cord has been the standard of 
care in the initial management of testis cancer for almost 100 years.20 However in a recent review 
regarding the implications of scrotal violation in testis cancer, Capeluto et al reported on a meta-analysis 
of 1,182 patients, scrotal violation had occurred in 206 patients. They found no statistical differences in 
distant recurrence or survival, implying that scrotal violation may not necessarily carry a worse prognosis. 
Distant spread of testis cancer occurs most commonly to the pulmonary region, with 
intraparenchymal pulmonary involvement. Subsequent spread is to the liver, viscera, brain and bone, with 
bony secondaries being encountered late in the course of the disease.21
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In summary, with the notable exception of choriocarcinoma, testicular cancer generally spreads in a 
predictable pattern. This has led to the development of new surgical techniques, which provide accurate 
pathological staging while at the same time providing therapeutic benefit. These techniques are also 
associated with reduced morbidity when compared to the classic full retroperitoneal lymphadenectomy 
(RPL). 
PREDICTION OF METASTATIC POTENTIAL 
In general, patients with clinical stage I NSGCT have a 20 - 30% incidence of micrometasteses in 
retroperitoneal lymph nodes. In addition follow-up studies of these patients have shown that visceral 
metastases occur in approximately 10%. Therefore, in theory approximately 70% of patients with clinical 
stage I NSGCT could be cured by radical orchiectomy alone. Studies to investigate this dilemma were 
initiated in the United Kingdom in 1979, and in Denmark in 1980. 22,23 These studies showed that the 
relapse rate after orchiectomy alone was approximately 30%. More than 90% of relapses occur within the 
first 2 years after orchiectomy; median time to relapse was 4 to 5 months after orchiectomy. Less than 
10% of relapses occur later than 2 years after orchiectomy. Fifty percent of relapses occur in the 
retroperitoneum and 30% of relapses occur without elevation of tumor markers. One third of relapses 
occur in the lung and 12% of relapses occur with elevation of tumor markers as the only sign of tumor 
recurrence. 
Several studies have investigated prognostic factors that predict relapse. A study performed by the 
MRC in the United Kingdom described four prognostic factors;24 vascular invasion, lymphatic invasion, 
the presence of embryonal carcinoma and the absence of yolk sac tumor. A prognostic index was 
subsequently created based on these factors. Patients with four positive prognostic factors were found to 
have a 46% risk of relapse compared with 21% for those with 2 factors and 16% for those with one factor. 
No relapses occurred in patients without any risk factors.25 In addition, primary tumor extent has also 
been shown to have prognostic significance.4 Clinical stage I NSGCT is therefore no longer managed as a 
homogeneous disease, rather treatment may now be individualized according to the likelihood of positive 
retroperitoneal lymph nodes. Patients with low risk of having positive nodes have the option of entering 
an observation protocol and thus may be spared the morbidity of adjuvant therapy. However, despite 
prognostic criteria, it is still not possible to establish highly accurate distinctions between patients who 
should and those who should not receive adjuvant therapy. In the MRC study in the United Kingdom the 
high risk group constituted less than 25% of all patients and most importantly less than half of all 
relapses.23 In a recent report, the long term outcome results of a prospective surveillance trial for clinical 
stage I NSGCT were described. With a median follow-up of 11.3 years, 74.3% of patients remained 
disease free, while the remainder experienced relapse. All relapses occurred within 2 years, the median 
time to relapse was 5 months. Significant indicators of relapse during surveillance were a predominant 
embryonal carcinoma histology and vascular invasion. In patients with neither of these two risk factors, 
the relapse rate was 12%, none of these patients died of their disease.26
STAGING TESTIS CANCER 
There are both clinical and pathological staging systems for NSGCT (Tables 1 and 2). Most systems in 
use today are a variation on the one proposed by Boden and Gibb in 1951.27 Low stage disease refers to 
clinical stages I (A) and IIA (B1) disease, whereas high stage disease encompasses stages IIB (B2), IIC 
(B3), and III (C) disease. This distinction between low and high stage disease is important, as it 
determines, to a large degree, the adjuvant therapy that the patient receives. While the clinical staging 
system is based predominantly on CT scan and chest X- Ray, pathologic staging is based on the surgical 
findings and the surgical specimens obtained at radical orchiectomy and RPL. The staging error 
associated with clinical staging is therefore removed by pathologic staging. 
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TABLE 1 
CLINICAL STAGING SYSTEMS FOR TESTICULAR CANCER 
BODEN/GIBB:  ROYAL MARSDEN HOSPITAL:  
A (I): Tumor confined to the testis I 
B (II): Spread to regional nodes IIA: < 2cm 
IIB: > 2cm, < 5cm 
IIIC: > 5cm 
C (III): Spread beyond 
retroperitoneal nodes 
III: Supraclavicular, nodal or 
mediastinal involvement 
IV: Extralymphatic involvement 
TABLE 2 
PATHOLOGICAL STAGING 
American Joint Committee on Cancer TNM 
Classification  SKINNER  
Primary tumor (T) - extent of the primary tumor is  
classified after radical orchiectomy  
pTX - Primary tumor cannot be evaluated i.e. radical 
orchiectomy not yet performed. 
pT0 - No evidence of primary tumor  
(histologic scar in the testis) 
pTIS - Carcinoma in situ, i.e. pre-invasive stage 
pT1 - Tumor limited to the testis, including the rete testis 
pT2 - Tumor invades beyond the tunica albuginea or into the 
epididymis 
pT3 - Tumor invades the spermatic cord 
pT4 - Tumor invades the scrotum  
A: Confined to the 
testis 
Regional lymph nodes (N)  
NX - Regional lymph nodes cannot be assessed  
N0 - No regional lymph node metastasis 
N1 - Metastasis in a single lymph node  
N2 - Metastasis in a single lymph node 2 cm or 2cm, no extra-
nodal extension less in greatest dimension, or multiple 
lymph nodes, none more than 5 cm in greatest dimension 
N3 - Metastasis in a lymph node more than 5 cm in greatest 
dimension  
B: Spread to the 
retroperitoneum 
BI: < 6 positive 
nodes, no node >  
BII: > 6 positive 
nodes, any node 
> 2 cm  
BIII: massive 
retroperitoneal 
disease 
Distant metastasis (M)  
MX - Presence of distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis  
C: Metastatic 
disease 
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RETROPERITONEAL LYMPHADENECTOMY (RPL) IN GCT OF THE TESTIS 
RPL-I 
This dissection is performed on patients with no clinical signs of spread to the retroperitoneum, and no 
surgically visible disease, i.e. clinical stage I disease. The surgical technique employed is either a 
template or nerve sparing technique. Therefore sympathetic nerves responsible for antegrade ejaculation 
are preserved, resulting in normal ejaculatory function in the vast majority of patients undergoing RPL-I. 
RPL-II 
This procedure is performed on patients with low volume clinically demonstrable disease, or visible 
disease at the time of surgery, i.e. clinical stage IIA or IIB disease. The surgical boundaries are generally 
wider than in RPL-I, usually bilateral above the inferior mesenteric artery and in most cases bilateral 
below the mesenteric artery as well. The lumbar sympathetics and the hypogastric plexus are carefully 
preserved, resulting in preservation of ejaculation in experienced hands in over 95% of patients 
undergoing RPL-II. 
RPL-III 
This procedure is performed on patients who have failed primary therapy, either primary chemotherapy, 
or primary retroperitoneal node dissection and who have either retroperitoneal recurrences or a persistent 
retroperitoneal mass detected radiographically (usually by CT scan). In selected cases nerve sparing 
techniques maybe employed.5
MANAGEMENT OF CLINICAL STAGE I DISEASE 
• SURVEILLANCE VS ADJUVANT THERAPY  
The decision to place a patient on a surveillance protocol or to opt for adjuvant therapy in the form of 
either RPL-I or chemotherapy depends on a number of factors, such as risk factors for disease relapse, 
patient compliance and local expertise with respect to performance of the surgical procedure. 
• ADVANTAGES OF RPL-I  
1. Thirty percent of patients with clinical stage I NSGCT have pathologic stage II disease.  
2. Accurate pathologic staging allows for earlier definition of further treatment options.  
3. RPL-I is both a staging and a therapeutic procedure.  
4. Follow-up after RPL-I is significantly less intensive than patients followed on surveillance 
protocols and therefore less expensive.  
5. Anxieties, which inevitably accompany the uncertainties associated with a surveillance 
protocol, are eliminated by surgical intervention.  
MANAGEMENT OF CLINICAL STAGE II DISEASE 
The most appropriate therapy for patients with clinical stage II NSGCT is controversial. Debate centers 
around the role of RPL-II vs chemotherapy and also around the role of post RPL chemotherapy. 
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There is general agreement that clinical stages IIC and III disease be managed initially with 
chemotherapy, and that surgery should be reserved for residual retroperitoneal masses. The initial 
management of clinical stages IIA and IIB disease, however, remains controversial. At the Brigham and 
Womenís Hospital most patients who present with clinical stage IIA disease undergo RPL-II. 
Furthermore, patients with < 3cm of nodal involvement also undergo RPL-II, while chemotherapy is 
generally recommended for those patients with > 3cm of nodal involvement.  
• ADJUVANT CHEMOTHERAPY FOLLOWING RPL-II  
The role of adjuvant chemotherapy following RPL-II vs. an expectant approach has been 
addressed by a number of investigators.28,29 Richie reviewed 39 patients with pathologic stage II 
disease who were carefully followed post RPL-II. Relapses occurred in only 8% of patients, all of 
whom were rendered disease free with 3 to 4 cycles of chemotherapy.28 In this study therefore 
immediate post RPL-II chemotherapy would have benefited only a small number of patients. In 
contrast, a randomized multi-center study reported a 48% relapse rate for patients with pathologic 
stage II disease, following RPL-II.30 These two studies highlight the fact that results from 
institutions where RPL is performed frequently, may not parallel results from large cooperative 
trials in which some centers contribute relatively small numbers of patients. 
Following RPL-II the decision to administer two cycles of chemotherapy depends on a 
number of factors: tumor volume, number of positive nodes, presence of vascular invasion in the 
primary tumor and histology of the primary tumor. Expectant management is appropriate in 
patients with fewer than 6 positive nodes (all of which are less than 2cm in diameter), with no 
positive margins. For patients with more than 6 positive nodes or high volume disease, two cycles 
of chemotherapy are given following RPL-II.31 This protocol has achieved excellent remission 
rates. For patients who develop a recurrence while being treated expectantly, chemotherapy is 
employed at that stage, once again with excellent remission rates.  
SURGICAL MANAGEMENT OF ADVANCED NSGCT: RPL-III 
RPL-III in patients with advanced NSGCT provides essential information for the future management of 
the patient:  
• Evaluates the response to chemotherapy.  
• Removes viable GCT, thus achieving a complete response to chemotherapy and surgery.  
• Directs the need for further therapy.  
Approximately 30% of patients with high volume metastatic NSGCT will experience a partial remission 
following cisplatin based chemotherapy and are therefore candidates for RPL-III, in addition to those 
patients who recur in the retroperitoneum following an incomplete node dissection for low stage disease. 
Partial remission is defined as normal tumor markers in combination with radiographic evidence of 
disease in the chest, abdomen, mediastinum, neck or elsewhere. 
Persistent or recurrent retroperitoneal mass: Histopathology and implications. 
Early retrospective studies revealed that RPL-III defines three subsets of patients based on 
histopathological analysis of the resected specimen: 40% - necrosis/fibrosis; 40% - adult teratoma; 20% - 
residual NSGCT.32,33 Therefore approximately 60% of patients with evidence of a residual mass on post-
chemotherapy imaging studies will either have viable cancer or teratoma. A more recent study showed 
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that the likelihood of malignancy in postchemotherapy resected tumor was 13%, with the remainder of 
tumor specimens containing teratoma or necrosis.34
The finding of only necrotic/fibrotic tissue implies that no further treatment is required.35 However 
patients with viable GCT require an additional two cycles of chemotherapy. Fox et al36 reported a series of 
27 patients who received additional cisplatin-based chemotherapy whereas 7 did not. Disease free survival 
was 70% in the chemotherapy group, while all 7 patients who did not receive additional chemotherapy 
relapsed. The rationale to resect residual teratoma is multi-factorial: firstly, by resecting residual teratoma 
the growing teratoma syndrome is avoided, in which indolent growth causes complications from local 
progression;37 secondly, malignant transformation of mature teratoma to sarcoma and adenocarcinoma 
which is resistant to chemotherapy has been well described;38 thirdly, there is a risk of recurrent viable GCT 
in teratoma, with no difference in incidence between mature and immature teratoma.39
RPL-III: Indications and Patient Selection 
Despite the well described hazards of residual viable GCT in the retroperitoneum following 
chemotherapy, as well as recurrent retroperitoneal GCT following RPL-I or RPL-II, the indications for 
RPL-III are controversial and there are no clear guidelines. The presence of elevated tumor markers, 
however, remains the only generally accepted contraindication to adjunctive surgery in patients after 
chemotherapy.40 The management of patients whose tumor markers have normalized following 
chemotherapy ranges from observation, irrespective of the results of imaging studies, to surgery for all 
patients.41,42 A residual mass is usually detected by CT scan following chemotherapy; however, the 
definitions of a normal CT scan differ from one institution to another. Definitions include: no visible 
mass, lymph nodes no larger than 1 cm and lymph nodes less than 1.5 cm to 2 cm in diameter.37
In view of the well described complications related to RPL-III, patient selection plays an important 
role in excluding those patients who are unlikely to have viable disease. Donohue et al43 found that in 
cases where no teratomatous elements were detected in the primary tumor and a greater than 90% 
decrease was seen in the volume of retroperitoneal disease by sequential CT scans, viable germ cell tumor 
or teratoma was not seen in the resected specimen. Fossa et al42 reported on 37 patients who underwent 
RPL-III despite negative CT scans following chemotherapy; teratoma was found in 30% while 3% were 
found to have NSGCT. The volume of teratoma was small, and may thus not be clinically significant to 
justify a blanket policy of RPL-III despite negative CT scan findings. Toner et al34 reported on 185 
patients who underwent RPL-III after chemotherapy; in this series, no factors could be found that could 
reliably predict patients who had residual viable malignancy or teratoma in the retroperitoneum. In view 
of this RPL-III was recommended for all patients with residual abnormalities on imaging of the 
retroperitoneum, and in all patients with an initial mass of greater than 3 cm regardless of the post 
chemotherapy radiological findings.32,33 An international data set was recently collected comprising data 
from six study groups. Logistic regression analysis was used to estimate the probability of necrosis and 
the ratio of cancer and mature teratoma, in patients who were treated with cisplatin-based chemotherapy 
for metastatic NSGCT, and who obtained normal tumor markers prior to resection. Multivariate 
combination of predictors yielded reliable models, which discriminated necrosis well from other 
histologies, but which discriminated cancer only reasonably well from mature teratoma.44
While there are statistical correlationís with various factors such as degree of tumor shrinkage, size of 
residual mass, pre-chemotherapy tumor markers and teratomatous elements in the primary specimen, the 
risk of a false negative prediction is approximately 20%.34,42
Complications of RPL III 
RPL-III is a technically very demanding procedure, which sometimes entails a combined abdominal and 
thoracic approach. Loss of ejaculation has been well documented in patients undergoing RPL-III. In a 
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recent study 25.9% of patients were reported to have absence of ejaculation following RPL-III. In this 
study, the volume of tumor resected was higher in those patients who had absence of ejaculation than in 
those patients with preservation of ejaculation. In addition, absence of ejaculation was reported 
significantly more often in patients with right paracaval/interaortocaval tumor (34.5%), than in those with 
left para-aortic tumor (16.7%).45
Nerve sparing techniques have been successfully employed in a subset of these patients.5 In a recent 
review of 472 patients who underwent RPL-III, 93 (19.7%) were subjected to nerve sparing procedures, 
mean size of residual disease on CT scan prior to the procedure was 6.3 cm (range 1 to 19). In this subset 
of patients 76.5% reported normal ejaculation and ten pregnancies were conceived. Testis cancer recurred 
in 6 patients but no tumor was retroperitoneal. Therefore, nerve sparing RPL-III appears to be viable in a 
subset of patients with limited volume and lateralized disease, without compromising cancer surgery 
outcomes, while preserving ejaculation.5
Occasionally, resection of the infrarenal vena cava is necessary and has been well described.46,47 In 
addition, aortic tube grafts may be necessary to replace aortic segments which are damaged by 
subadvential dissection.48 The complication rate is therefore directly related to the complexity of the 
dissection; in addition, complications related to the cumulative toxicity of chemotherapeutic agents are of 
particular relevance to patients undergoing RPL-III following chemotherapy. 
Of particular relevance to post-chemotherapy patients is the association of restrictive lung disease in 
patients who have received bleomycin as part of their chemotherapy protocol. Bleomycin induced 
pulmonary toxicity is associated with a mortality rate which approaches 50%. In a recent report, Baniel et. 
al.49 reviewed the surgical morbidity of 603 patients who underwent RPL after primary chemotherapy for 
stage II and III testis cancer. The complication rate was 20.7% and the mortality rate was 0.8%. 
Pulmonary complications were the most frequent cause of severe morbidity: 6 patients developed adult 
respiratory distress syndrome, the underlying cause of which was a combination of bleomycin induced 
pulmonary toxicity, together with large volume retroperitoneal and pulmonary disease resected in this 
subset of patients. 
CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NSGCT 
While chemotherapeutic trials were being conducted, it became clear that prognoses varied and that 
patients should therefore be divided into low and high risk categories. For those patients predicted to have 
a more favorable outcome i.e. good risk, the goals have been to maintain high cure rates while reducing 
treatment related toxicity.3,50 On the other hand the goal of treating poor risk patients has been to improve 
the proportion of patients achieving a complete response, while at the same time achieving tolerable 
treatment side effects. Using data from the cisplatin, vinblastine, bleomycin (PVB) studies, the Indiana 
University staging system was developed (Table 3). This classification uses clinical parameters to divide 
patients with disseminated testis cancer into three stages - minimal, moderate and advanced disease. 
While minimal and moderate disease is good risk and is associated with high complete response rates to 
cisplatin based chemotherapy and low risk of relapse, advanced disease is poor risk disease and therefore 
has a lower complete response rate and a higher rate of relapse. Although the Indiana University system is 
easy to use it does not take into account the important role that the tumor markers HCG (human chorionic 
gonadotropin), AFP (alpha fetoprotein) and LDH (lactate dehydrogenase) play in this disease.50 Bosl et al 
developed one of the first validated models to mathematically categorize patients into prognostic 
groups.51 The variables in the model include the number of metastatic sites as well as HCG and LDH. 
Several other models have been published affirming the principles that the Bosl model described.50,52 The 
International Germ Cell Cancer Collaborative Group recently published a clinically based prognostic 
classification for GCT in which the following adverse factors were identified: mediastinal primary site; 
degree of elevation of alpha-fetoprotein (AFP), human chorionic gonadtrophin (hCG) and lactate 
dehydrogenase (LDH); presence of nonpulmonary metasteses such as liver, bone and brain. Integration of 
these factors produced the following groupings: good prognosis, comprising 60% of GCT with a 91% 5- 
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TABLE 3 
INDIANA UNIVERSITY STAGING SYSTEM FOR DISSEMINATED DISEASE:  
MINIMAL AND MODERATE STAGES CONSTITUTE GOOD RISK DISEASE  
Minimal  
1. Elevated markers only 
2. Cervical nodes (± nonpalpable retroperitoneal nodes) 
3. Unresectable, nonpalpable retroperitoneal disease 
4. Fewer than 5 pulmonary metastases per lung field and largest < 2 cm (± 
nonpalpable retroperitoneal nodes)  
Moderate  
5. Palpable abdominal disease mass only 
6. Moderate pulmonary metastases: > 5 - 10 metastases per lung field and 
largest < 3 cm or solitary pulmonary metastasis of any size > 2 cm (± 
nonpalpable retroperitoneal nodes)  
Advanced 
7. Advanced pulmonary metastases: > 10 pulmonary metastases per lung 
field, or multiple pulmonary metastases with largest > 3 cm (± 
nonpalpable retroperitoneal nodes) 
8. Palpable abdominal mass plus supradiaphragmatic disease 
9. Liver, bone, or CNS metastasis  
year survival rate; intermediate prognosis, comprising 26% of GCT with a 79% 5-year survival rate; and 
poor prognosis, comprising 14% of GCT with a 48% 5-year survival rate53 (Table 4). 
Hopefully the widespread use of a standardized prognostic model will result in more patients 
benefiting from chemotherapeutic regimens with fewer side effects.53,54
CHEMOTHERAPY IN GOOD RISK PATIENTS 
The first prospective trials in good risk patients compared the VAB-6 regimen (vinblastine, dactinomycin, 
bleomycin, cyclophosphamide and cisplatin) with a two drug regimen of etoposide plus cisplatin (EP).55 
The results of this trial demonstrated equivalence but with a toxicity favoring EP. In long term follow-up 
no excess of late relapse was found in patients treated with 4 cycles of EP.14 Thus 4 cycles of EP with 
cycles repeated every 21 - 28 days has become one of the international standards for good risk disease. 
Einhorn et al compared 4 cycles of BEP (bleomycin, etoposide, cisplatin) to 3 cycles of BEP. One hundred 
eighty-four patients were entered into this trial. Overall 99% of patients with minimal advanced stage disease 
and 95% of patients with moderate advanced stage disease achieved disease free status. Only 5.6% of patients 
relapsed and the overall disease free survival was the same in both arms of this study, which demonstrated that 
elimination of the fourth cycle of BEP reduced toxicity without affecting survival.14
In a trial conducted by the Eastern Cooperative Oncology Group (ECOG), 178 good risk patients 
were randomized to receive three cycles of EP either with or without bleomycin.56 Myelosuppression was 
slightly greater in the BEP arm (57% versus 45%); no pulmonary toxicity was seen in either group. This 
trial was stopped early because of a statistically significant increase in the number of adverse events 
(defined as death, persistent or progressive cancer, or relapse) in patients not receiving bleomycin. Of the 
86 patients treated with BEP, 95% achieved a disease-free status and 86% were continuously disease free, 
compared with 90% and 70% respectively in the EP arm. This data supports the necessity of including 
bleomycin when three cycles of cisplatin based chemotherapy are used. 
 324
Steele and Richie: Nonseminomatous Testicular Cancer  TheScientificWorldJOURNAL (2004) 4 (S1), 316–329
 
TABLE 4 
INTERNATIONAL GERM CELL CONSENSUS CLASSIFICATION FOR NSGCT: 
GOOD PROGNOSIS: Primary tumor - testis or retroperitoneal  
and 
No non-pulmonary visceral metastases  
and  
Good markers - all of:  
AFP < 1000ng/ml and 
hCG < 5000 iu/l and  
LDH < 1.5 x upper limit of normal  
INTERMEDIATE PROGNOSIS: Primary tumor - testis or retroperitoneal  
and  
No non-pulmonary visceral metastases  
and  
Intermediate markers - any of:  
AFP > 1000 and < 10,000 ng/ml or 
hCG > 5000 and < 50,000 iu/l or 
LDH > 1.5 x N and < 10 x N  
POOR PROGNOSIS: Mediastinal Primary  
or  
Non-pulmonary visceral metastases  
or  
Poor markers - any of:  
AFP > 10,000 ng/ml or 
hCG > 50,000 iu/l or 
LDH > 10 x upper, limit of normal  
Carboplatin was chosen as a substitute for cisplatin in a trial performed by Bajorin et al., because of 
its better toxicity profile, i.e. fewer renal, otologic and neurologic toxicities.57 A durable complete 
response was achieved in only 76% of patients treated with etoposide and carboplatin (EC) compared to a 
durable complete response rate of 87% in patients treated with EP.35 This trial therefore confirmed the 
efficacy of four cycles of EP and also showed that carboplatin cannot be substituted for cisplatin in this 
subset of patients. 
CHEMOTHERAPY IN POOR RISK PATIENTS 
Clinical trials involving patients with advanced disease have focused on enhancing response rates and 
improving survival. Poor risk patients are fortunately rare and usually present with primary mediastinal 
GCT.58 Marked elevation of one or more tumor markers (beta-human chorionic gonadotropin, alpha-
fetoprotein and lactate dehydrogenase) is a common reason for inclusion into the poor risk group. In 
addition the presence of liver, bone or brain metastases as well as increasing bulk of disease are also used 
as inclusion criteria for the poor prognostic group.58,59 Although there are a large number of phase II 
studies for the treatment of poor risk patients, none of them has been sufficiently encouraging to be 
considered as a standard therapy. 
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Several trials have been conducted using conventional dose chemotherapy. Ifosfamide in combination 
with etoposide and cisplatin (VIP) has been compared to BEP.60 VIP proved to be more toxic but 
equivalent to BEP with respect to efficacy. 
Impressive results have been reported from single center studies describing the use of cyclic 
alternating chemotherapy regimens. These regimens expose the GCT to a wide variety of 
chemotherapeutic drugs in the hope of preventing drug resistance. The results however have not been 
validated by randomized trials. 
Due to the fact that high dose chemotherapy given as second or third line therapy was associated with 
a very high morbidity and mortality rate, the role of chemotherapy with autologous bone marrow 
transplantation (ABMT) was investigated.61,62 Twenty eight poor risk patients were entered into a trial in 
which high dose chemotherapy was given to those patients whose tumor markers exhibited a prolonged 
decline following standard dose therapy. When the results in this subset of patients were compared to the 
prior experience in poor risk patients, there appeared to be a survival benefit.63 A French cooperative 
group reported their experience with high dose chemotherapy followed by ABMT. Patients were 
randomized to receive either conventional or high dose chemotherapy in combination with ABMT. 
However, 28% of patients randomized to receive high-dosed therapy did not receive this treatment and no 
statistical differences were apparent between the 2 groups of patients.17
Growth factor and peripheral blood stem cell support have been used in combination with dose 
intensification of all cycles of chemotherapy. In a study involving 77 poor risk patients, dose escalation of 
the chemotherapy regimen was combined with granulocyte-macrophage-colony stimulating factor (GM-
CSF). Overall 67% of patients achieved progression-free survival.64
CHEMOTHERAPY FOR RELAPSED TESTIS CANCER 
For the 20% to 30% of patients with advanced GCT, who do not achieve complete response to first line 
chemotherapy, second line salvage chemotherapy remains an option.65,66
The current standard chemotherapy that serves as a basis for comparison is vinblastine, ifosfamide 
and cisplatin (VeIP).66 As second line therapy 33% to 69% of patients achieved a complete response with 
ifosfamide based regimens, which was found to be durable in approximately 50% of patients.67 In view of 
this, ifosfamide is generally considered to be a standard first line salvage therapy. Approximately 25% to 
50% of patients who relapse following chemotherapy have been shown to achieve a complete response to 
high dose carboplatin and etoposide with and without oxazophosphorine (cyclophosphamide, ifosfamide) 
and ABMT.68 Forty three percent of patients achieved a complete response, 27% remained alive and 
disease free at 8 months of follow-up. 
Favorable pretreatment prognostic factors for survival to treatment with conventional dose salvage 
therapy include a prior complete response to cisplatin based chemotherapy and a testicular primary site. 
Prognostic factors that predict an inferior long term disease free survival include an initial incomplete 
response to cisplatin based chemotherapy and a primary mediastinal site of disease.68 These poor 
prognostic factors predict a very poor outcome and the role of standard chemotherapy is thus limited. 
Aggressive surgery may offer a reasonable alternative as may radiotherapy, in addition high dose 
chemotherapeutic regimens may have a role.35
CONCLUSIONS 
Advances in the management of GCT of the testis have led to a multimodal approach which has resulted 
in the vast majority of patients being cured of their disease. More than 90% of patients with newly 
diagnosed GCT will be cured. RPL not only provides accurate data for pathological staging, but is also 
therapeutic in low stage disease. Moreover RPL plays an essential role in the management of high stage 
disease with respect to both directing further patient management and providing long-term disease free 
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survival following complete resection of residual teratoma. Precise surgical technique however is 
mandatory to ensure disease free survival. Patients presenting with advanced disease are stratified into 
good, intermediate and poor risk groups. Therapy for good risk disease consists of either four cycles of 
EP or three cycles of BEP; resulting complete response rates are high. On the other hand poor risk 
patients require intensive and specialized management and should be referred to an appropriate center 
with expertise in this area. ABMT or stem cell support combined with high dose chemotherapeutic 
regimens (VeIP) can be successfully used to treat patients who relapse following first line chemotherapy. 
However patients who relapse with poor prognostic features do not respond well to high dose 
chemotherapy, and may thus require aggressive surgery or radiotherapy.
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